Acriflex 0.25%

Acriflex 0.25%

Overdose

With external use, cases of overdose are unknown.

Shelf life

Three years unopened.

Incompatibilities

Solution for external use, solution for alcoholic external use, Solution for topical and external use ,Solution for the preparation of dosage forms, Spray for external use [alcoholic], Vaginal SuppositoriesAerosol for external use

Pharmaceutically incompatible with soap, alkalis and other anionic compounds (colloids, gum arabic, carboxymethylcellulose).

Enhances the effect of cationic detergents. Incompatible with soap and other anionic detergents, with substances containing anionic groups (saponins, sodium lauryl sulfate, sodium carboxymethylcellulose).

List of excipients

Arlatone 983 S

Cetostearyl Alcohol

Liquid Paraffin

Dimeticone 20

Glycerol (E422)

Quinoline Yellow Lake (E104)

Purified Water

Undesirable effects

Solution for external use, solution for alcoholic external use, Solution for topical and external use ,Solution for the preparation of dosage forms, Spray for external use [alcoholic], Vaginal SuppositoriesAerosol for external use

Allergic reactions (rash), dry skin, itching, dermatitis.

Rarely-allergic dermatitis.

Preclinical safety data

Not applicable.

Pharmacotherapeutic group

  • Antiseptics and disinfectants

Pharmacodynamic properties

Solution for external use, solution for alcoholic external use, Solution for topical and external use ,Solution for the preparation of dosage forms, Spray for external use [alcoholic], Vaginal SuppositoriesAerosol for external use

Has antimicrobial activity against Gram-negative and Gram-positive bacteria (Treponema spp., Neisseia gonorrhoeae, Tricyomonas spp., Chlamidia spp.) diseases, pathogens, nosocomial infections and tuberculosis, infections of viral etiology (hepatitis b virus, HIV, herpes, ротавирусные gastroenteritis, энтеровирусные infections, influenza and other syncytial-viral infections), дробных fungi of the genus Candida, dermatophytes.

Prolonged action-up to 4 hours.

Active against vegetative forms of Gram-positive and Gram-negative bacteria, yeasts, dermatophytes, lipophilic viruses. Maintains activity in the presence of blood and pus. It has surfactant properties and helps to clean wounds, ulcers. Does not cause damage and irritation to the skin.

Pharmacokinetic properties

Intact skin is not absorbed.

Date of revision of the text

03/08/2016

Marketing authorisation holder

Thornton & Ross Limited

Linthwaite

Huddersfield

West Yorkshire

HD7 5QH

United Kingdom

Special precautions for storage

At a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life of the Anti-Angina drug® Formula3 года.

Do not use after the expiry date which is stated on the packaging.

Nature and contents of container

Tablets for resorption 1 table.
active substance:  
tetracaine hydrochloride 0.2 g
chlorhexidine diacetate 2 mg
ascorbic acid 50 mg
excipient: levomentol, saccharin, sorbitol, silicon dioxide, magnesium stearate, anise flavour, mint flavour, azorubin colour (E122)  
Presentation

Tablets for resorption. By 2, 4, 6, 8, 10, 12 tabl. in PVC / aluminium blister. By 1, 2, 3, 4, 5, 10, 15 BL. in a cardboard package.

Marketing authorisation number(s)

PL 00240/0116

Special warnings and precautions for use

Acriflex contains chlorhexidine. Chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. The prevalence of chlorhexidine hypersensitivity is not known, but available literature suggests this is likely to be very rare. Acriflex should not be administered to anyone with a potential history of an allergic reaction to a chlorhexidine-containing compound.

Keep away from the eyes.

Avoid contact with the brain, meninges and middle ear. Not for use in body cavities.

Effects on ability to drive and use machines

None known.

Special precautions for disposal and other handling

For general use, apply freely and smooth gently into the skin. For cuts, abrasions, burns, etc. spread freely and, if necessary, cover with a dressing.

There are no recommended dosage schedules as the product is for use as needed.

Date of first authorisation/renewal of the authorisation

29/03/2005